Skip to main content
. Author manuscript; available in PMC: 2011 Sep 15.
Published in final edited form as: J Control Release. 2010 Jun 2;146(3):341–348. doi: 10.1016/j.jconrel.2010.05.032

Figure 5.

Figure 5

Production of anti-OVA IgG1 antibodies by C57BL/6 mice treated with OVA co-delivered with PBS, CFA, or polymer SC. Antibody concentrations were measured by ELISA from serum collected at different times. No detectable anti-OVA antibodies were produced from mice receiving SC without OVA. Data are shown as replicates with means represented as a line (n=5-7 mice). * indicates significant difference between treatment group and negative control. ND indicates none of the collected sera samples contained detectable amount of antibody.